AVEO PHARMACEUTICALS INC's ticker is AVEO and the CUSIP is 053588109. A total of 55 filers reported holding AVEO PHARMACEUTICALS INC in Q3 2014. The put-call ratio across all filers is 27.25 and the average weighting 1.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $42,000 | -26.3% | 67,500 | 0.0% | 0.00% | – |
| Q3 2019 | $57,000 | -70.8% | 67,500 | -76.7% | 0.00% | – |
| Q2 2019 | $195,000 | +143.8% | 289,856 | +196.4% | 0.00% | – |
| Q1 2019 | $80,000 | -92.8% | 97,789 | -86.0% | 0.00% | -100.0% |
| Q4 2018 | $1,116,000 | -43.1% | 697,500 | +17.7% | 0.00% | 0.0% |
| Q3 2018 | $1,961,000 | +1385.6% | 592,442 | +913.4% | 0.00% | – |
| Q2 2018 | $132,000 | -88.5% | 58,459 | -85.2% | 0.00% | -100.0% |
| Q1 2018 | $1,149,000 | +34.9% | 396,202 | +29.7% | 0.00% | 0.0% |
| Q4 2017 | $852,000 | -27.0% | 305,481 | -4.5% | 0.00% | 0.0% |
| Q3 2017 | $1,167,000 | – | 319,900 | +615092.3% | 0.00% | – |
| Q3 2014 | $0 | -100.0% | 52 | -99.9% | 0.00% | – |
| Q2 2014 | $86,000 | +4200.0% | 86,325 | +3832.8% | 0.00% | – |
| Q1 2014 | $2,000 | +100.0% | 2,195 | +67.7% | 0.00% | – |
| Q4 2013 | $1,000 | 0.0% | 1,309 | +153.2% | 0.00% | – |
| Q3 2013 | $1,000 | -96.0% | 517 | -94.7% | 0.00% | – |
| Q2 2013 | $25,000 | – | 9,715 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Greylock XI GP Limited Partnership | 584,004 | $1,068,000 | 100.00% |
| GREAT POINT PARTNERS LLC | 2,325,000 | $4,255,000 | 1.89% |
| Sarissa Capital Management LP | 2,570,759 | $4,704,000 | 1.60% |
| Deer VI & Co. LLC | 675,242 | $1,236,000 | 0.68% |
| Palo Alto Investors LP | 1,200,800 | $2,197,000 | 0.16% |
| Baupost Group | 3,829,350 | $7,008,000 | 0.11% |
| Gruss Capital Management LP | 533,253 | $976,000 | 0.05% |
| Granahan Investment Management | 676,451 | $1,238,000 | 0.04% |
| Fore Research & Management, LP | 674,200 | $1,233,000 | 0.04% |
| TFS CAPITAL LLC | 210,369 | $385,000 | 0.03% |